Skye Bioscience, INC Form 4 insider transactions

Keith Wayne Ward, a director at Skye Bioscience, Inc., acquired 35,000 stock options on February 29, 2024, exercisable at $14.56 per share.

Director Praveen Tyle of Skye Bioscience, Inc. was granted stock options to purchase 35,000 shares of common stock on February 29, 2024.

Tuan Tu Diep, Chief Development Officer of Skye Bioscience, was granted stock options and restricted stock units (RSUs) tied to market capitalization and stock price milestones.

Kaitlyn Arsenault, CFO of Skye Bioscience, reports the acquisition of stock options and restricted stock units (RSUs) based on specific market capitalization and stock price milestones.

Punit Dhillon, CEO of Skye Bioscience, was granted stock options and restricted stock units (RSUs) tied to market capitalization and stock price milestones.

Kaitlyn Arsenault, CFO of Skye Bioscience, reports the acquisition of restricted stock units and stock options based on performance milestones and time-based vesting.

Skye Bioscience CEO Punit Dhillon was granted stock options and restricted stock units (RSUs) tied to market capitalization and acquisition milestones.